On October 20th, the pharmaceutical and health conference of the 10th anniversary series of activities of Zhongyuan Bank, with the theme of "Technology driven Finance Empowering a Healthy Future", was successfully held in Zhengzhou. At the invitation of the conference, Dr. Yang Yinke, Chief Medical Officer of EMICRO Biomedicine Company, gave a special roadshow on "Innovative Drugs: Clinical Development of Next Generation BTK Inhibitors"; Li Peng, academician of the CAS Member and president of Zhengzhou University, made a keynote speech around the "Thinking about the future development of China's bio pharmaceutical industry"; Jiang Jiandong, academician of the CAE Member and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, made a keynote speech around the Shining Chinese Original Drugs.

  The biopharmaceutical industry is related to the national economy and people's livelihood, and is an important battlefield for the formation of new quality productivity. The pharmaceutical and health conference held in the eastern district of Zhengzhou aims to explore new trends and opportunities in the innovative development of the pharmaceutical and health industry with various sectors, and to explore new models and paths for technology finance to empower the innovative development of the pharmaceutical and health industry. About 130 leaders, industry experts, and enterprise representatives from relevant departments of the provincial capital of Henan Province attended the conference. Henan EMICRO Microbial Medicine Co., Ltd. attaches great importance to this conference and has sent two experts, Dr. Yang Yinke and Master Cao Chenghua, to attend. They are experts in innovative drug development, clinical medicine, and financing, with rich practical experience. At the meeting, two academicians and representatives from leading biopharmaceutical companies, including EMICRO Biomedicine, gave a wonderful roadshow that was related to the research and development of innovative anti-tumor drugs, drug development strategies, and clinical development of new generation BTK inhibitors. It was widely praised and praised by the attending leaders, experts, and audience.

In his speech, Dr. Yang Yinke not only talked about the seven major advantages and high drug efficacy of the company's newly developed anti-tumor innovative drug BTK inhibitor TM471-1, as well as the strategy for conducting clinical trials, but also mentioned the obstacles and problems that innovative drug companies face together, such as technology, innovation, risk, and financing. These are also issues that the conference is promoting improvement and solving in accordance with national policies, which has caused a warm response and resonance at the conference.

Henan EMICRO Microbial Medicine Co., Ltd. is a modern high-tech enterprise specializing in the research and development of innovative anti-tumor drugs. In November last year, the company's first class anti-tumor innovative drug BTK inhibitor TM471-1 was approved for national phase I clinical trials, filling a gap in the research and development of small molecule anti-tumor innovative drugs in Henan Province. At this conference, Dr. Yang Yinke and Master Cao Chenghua from EMICRO Biomedicine also met two academicians and created conditions for future exchanges and cooperation.

  河南知微生物医药有限公司是专业从事抗肿瘤创新药研发的现代化高科技企业。去年11月份，公司研发的1类抗肿瘤创新药BTK抑制剂TM471-1获批国家一期临床试验，填补了河南省在小分子抗肿瘤创新药研发领域的一项空白。在此次大会上，知微医药杨寅柯博士、曹承华硕士还结识了两位院士，并为今后的交流合作创造了条件。